Sermorelin Compassionate Use and Expanded Access: What Patients Need to Know in 2026

What "Compassionate Use" and "Expanded Access" Actually Mean for Sermorelin

True FDA compassionate use, formally called expanded access, is a pathway defined in 21 CFR Part 312 Subpart I that allows patients with serious or life-threatening conditions to receive an investigational drug outside of a clinical trial [1]. For sermorelin, this pathway does not currently apply in the way most patients assume.

Sermorelin is not under active clinical investigation with an open IND that accepts new patients. The FDA's original approval of sermorelin acetate (brand name Geref) was withdrawn when Serono discontinued the product in 2008, not because of safety signals but for commercial reasons [2]. That distinction matters: a drug withdrawn for commercial reasons rather than safety can still be compounded legally under 503A rules.

The 21 CFR 312 Expanded Access Framework

Under 21 CFR Part 312.310, a physician can submit an emergency IND application to the FDA for a single patient in as little as one business day for life-threatening situations [1]. The criteria are strict: the condition must be serious or immediately life-threatening, no comparable therapy must be available, and the potential benefit must outweigh the risk.

Adult growth hormone deficiency (AGHD) is a recognized condition, but it rarely meets the "immediately life-threatening" bar required for emergency IND approval. The standard process for AGHD involves formal diagnosis followed by FDA-approved recombinant human growth hormone (rhGH) products such as somatropin, not sermorelin [3].

Why Most Patients Do Not Qualify for Formal Expanded Access

Sermorelin sits in a regulatory gray zone. It is neither an approved finished drug product nor an active investigational drug with a sponsoring IND. Patients seeking sermorelin for anti-aging, body composition, or general wellness goals do not qualify for any formal expanded access mechanism because those indications are not classified as serious or life-threatening under 21 CFR 312.300 [1].

The practical access route for the overwhelming majority of patients is a licensed 503A compounding pharmacy, not an expanded access program.

How 503A Compounding Pharmacies Provide Legal Sermorelin Access

The most common and legally straightforward way to obtain sermorelin in 2026 is through a 503A compounding pharmacy operating under a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs, including peptides such as sermorelin, for individual patients when a licensed practitioner issues a prescription [4].

What 503A Means in Practice

A 503A pharmacy compounds drugs for specific patients, not for large-scale distribution. Each vial is prepared in response to a prescription bearing the patient's name. The pharmacy must be licensed in the state where the patient resides and must follow USP <797> sterile compounding standards.

Sermorelin acetate is on the FDA's 503A bulk drug substances list under review. The FDA published its most recent bulk substances evaluation framework in 2023, and sermorelin has not been placed on the list of substances that may not be compounded [4]. Providers and patients should verify current status at FDA's 503A Bulks page before initiating therapy.

Finding a Reputable Compounder

The Pharmacy Compounding Accreditation Board (PCAB) accredits 503A pharmacies that meet additional quality standards beyond state licensure. Choosing a PCAB-accredited pharmacy reduces the risk of sub-potent or contaminated preparations. A 2022 FDA inspection report found sterility failures in roughly 1 in 8 non-accredited sterile compounding facilities sampled, compared to a much lower rate among PCAB-accredited sites [5].

Prescription Requirements

A physician, nurse practitioner, or physician assistant licensed in the patient's state must issue the prescription. The prescription must include the patient's name, the compound name and strength, dosing instructions, and the prescribing provider's DEA or NPI number. Telehealth prescribers can issue this prescription in most states following a synchronous video consultation.

How to Get Sermorelin Cheaper: Practical Cost-Reduction Strategies

Sermorelin is not covered by commercial insurance or Medicare because it lacks an FDA-approved indication for adults. Cash-pay pricing at 503A compounding pharmacies typically runs $100, $350 per month depending on dose, vial size, and pharmacy location [6]. Several strategies can reduce this cost meaningfully.

Telehealth Platforms and Bundled Pricing

Many telehealth clinics bundle the prescriber consultation fee, laboratory work, and pharmacy coordination into a flat monthly membership. This bundled model can reduce the effective per-month cost compared to paying separately for an endocrinologist visit ($200, $400 out-of-pocket), lab draws ($80, $150 for an IGF-1 panel), and pharmacy fees. Comparing total program cost across two or three telehealth providers before committing is a straightforward way to benchmark pricing.

Cash-Pay Pharmacy Networks

Some compounding pharmacies participate in cash-pay discount networks or offer loyalty pricing for patients who commit to a three-month or six-month prescription. Requesting a 90-day supply rather than a 30-day supply frequently reduces the per-unit cost by 10 to 20% at pharmacies that charge a dispensing fee per order rather than per unit.

Manufacturer and Pharmacy Coupon Programs

Because sermorelin is compounded rather than manufactured under a brand name, traditional drug manufacturer copay cards do not apply. However, certain telehealth platforms negotiate volume pricing with partner pharmacies and pass a portion of that discount to patients. Asking the prescribing platform directly whether a partner pharmacy discount applies is a reasonable first step.

Dose Optimization to Reduce Waste

Adult protocols typically use 0.2 to 0.3 mg subcutaneous nightly [7]. Some providers begin patients at the lower end of this range. Starting at 0.2 mg nightly rather than 0.3 mg reduces monthly drug volume by roughly 33%, which translates directly to lower pharmacy costs while the provider assesses IGF-1 response at the three-month mark.

HSA and FSA Eligibility for Sermorelin

Sermorelin purchased with a valid prescription qualifies as an eligible medical expense under IRS Publication 502, which covers prescription medications [8]. Both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can be used to pay for sermorelin when a licensed provider has issued a prescription for a recognized medical condition.

The Prescription Requirement Is Non-Negotiable

An HSA or FSA cannot reimburse sermorelin purchased without a prescription or obtained from an unregulated online source. The IRS standard under Publication 502 explicitly requires that prescription medications be "prescribed by a physician" [8]. A compounding pharmacy receipt combined with the prescription documentation is sufficient for reimbursement claims.

Cosmetic or Wellness Use Is Not Covered

If sermorelin is prescribed solely for anti-aging or general wellness without a documented medical indication, HSA/FSA administrators may deny the claim under IRS rules that exclude cosmetic procedures and treatments not primarily intended to treat a specific condition [8]. Patients whose providers document a clinical indication, such as adult growth hormone deficiency, low IGF-1, or a condition supported by the Endocrine Society's AGHD guidelines, have a stronger basis for HSA/FSA reimbursement [3].

Practical Tip: Letter of Medical Necessity

Requesting a Letter of Medical Necessity (LMN) from the prescribing provider strengthens any HSA/FSA reimbursement submission. The LMN should state the diagnosis or clinical indication, the prescribed treatment, and why it is medically necessary. Most HSA/FSA administrators accept an LMN alongside the pharmacy receipt without further review.

FSA Rollover and Deadline Considerations

Traditional FSAs have a use-it-or-lose-it deadline, typically December 31, with an optional $640 rollover in 2026. Patients who know they will begin sermorelin therapy should time their FSA elections accordingly. HSAs have no rollover deadline and accumulate indefinitely, making them a better vehicle for patients with recurring peptide therapy costs.

Clinical Monitoring Requirements Under Endocrine Society Guidelines

Access to sermorelin at a reduced cost is only part of the equation. Safe use requires ongoing laboratory monitoring. The Endocrine Society's 2011 Clinical Practice Guideline on adult growth hormone deficiency, updated with supplemental guidance in 2019, recommends measuring IGF-1 levels every 1 to 2 months during dose titration and every 6 months once a stable dose is reached [3].

IGF-1 Targets and Dose Adjustment

The goal of sermorelin therapy is to stimulate endogenous GH pulsatility and raise IGF-1 into the mid-normal range for age and sex, typically the 50th, 75th percentile of the age-adjusted reference interval. Targeting the upper quartile without clinical justification increases the risk of side effects including edema, arthralgia, and carpal tunnel syndrome, which occurred in 2 to 4% of patients in rhGH trials and may occur at lower rates with secretagogue-based approaches [9].

A reasonable monitoring framework for sermorelin:

• Baseline: IGF-1, fasting glucose, HbA1c, thyroid panel, CBC
• Month 3: IGF-1, fasting glucose (dose adjustment visit)
• Month 6: IGF-1, fasting glucose, HbA1c
• Annually: Full metabolic panel, IGF-1, HbA1c, body composition if available

Glucose Monitoring Rationale

Growth hormone raises fasting glucose via hepatic gluconeogenesis. A 2019 meta-analysis of 22 rhGH trials (N=2,256) found that long-term GH therapy was associated with a modest but statistically significant increase in fasting glucose (mean difference 0.18 mmol/L, P<0.001) [9]. Sermorelin produces lower peak GH levels than exogenous rhGH because it relies on intact pituitary feedback, but baseline and periodic glucose monitoring remains standard practice.

Thyroid Function

GH axis activity can unmask subclinical central hypothyroidism by increasing T4-to-T3 conversion demands. The Endocrine Society guideline notes that thyroid function should be checked after GH or GH-secretagogue therapy is initiated in patients with known hypothalamic-pituitary disease [3].

Sermorelin vs. Other Growth Hormone Secretagogues: Access Comparison

Patients researching cost-effective access frequently compare sermorelin to other peptides in the same class, including ipamorelin, CJC-1295, and tesamorelin. Understanding the regulatory and access differences helps patients and providers make informed decisions.

Tesamorelin: The Only FDA-Approved GH Secretagogue for Adults

Tesamorelin (Egrifta SV) holds FDA approval for HIV-associated lipodystrophy. For that specific indication, it may be covered by insurance and is eligible for manufacturer patient assistance programs through Theratechnologies [10]. Outside of HIV-associated lipodystrophy, tesamorelin is prescribed off-label and faces the same access constraints as sermorelin.

Ipamorelin and CJC-1295: Compounding-Only Peptides

Ipamorelin and CJC-1295 are available only through 503A compounding pharmacies and have no FDA-approved finished drug product. In 2023, the FDA placed both peptides on the list of bulk drug substances that raise significant safety concerns, effectively restricting their compounding [11]. Sermorelin has not received the same restriction as of early 2026, which is one reason it remains the more accessible option among growth hormone secretagogues at 503A pharmacies.

Head-to-Head Cost Comparison

At current 503A market rates, sermorelin at 0.2 mg nightly runs approximately $100, $180 per month for a 30-day supply. Tesamorelin off-label compounding, where available, runs $250, $450 per month due to higher synthesis costs. The cost differential makes sermorelin the standard first-line secretagogue for cost-sensitive patients who do not have the HIV-associated lipodystrophy indication [6].

Pediatric Historical Context: How Sermorelin Got Its FDA Approval and Lost It

Sermorelin acetate was FDA-approved in 1997 under the brand name Geref for the treatment of idiopathic growth hormone deficiency in children. The approval was based on clinical data demonstrating that sermorelin stimulated pulsatile GH release and improved height velocity in prepubertal children with documented GHD [2].

Serono voluntarily withdrew Geref from the U.S. Market in 2008, citing commercial viability rather than safety concerns. The FDA's market withdrawal record confirms no safety-based recall was issued [2]. This commercial withdrawal is why sermorelin remains legally compoundable: a drug removed for business reasons, not for demonstrated harm, can be compounded under 503A provided it is not a copy of a commercially available product.

The absence of a commercially available branded product is actually what enables the 503A pathway for sermorelin today.

Regulatory Risks Patients and Providers Should Monitor in 2026

The regulatory environment for compounded peptides shifted meaningfully between 2023 and 2025, and sermorelin's status could change. The FDA's ongoing 503A bulks evaluation process reviews peptides on a rolling basis. If sermorelin were placed on the "Category 2" list (substances that may not be compounded due to safety concerns), 503A pharmacies would be required to stop dispensing it [4].

Providers and patients should check the FDA's current 503A bulks list at least every six months. The FDA also publishes warning letters to compounding pharmacies on its website; reviewing whether a prospective pharmacy has received a recent warning letter is a reasonable due-diligence step before initiating therapy [5].

A second regulatory risk involves state-level prescribing board actions. Several state medical boards issued guidance between 2023 and 2025 requiring additional documentation for peptide prescriptions. Patients using telehealth providers should confirm the prescriber is licensed in their state of residence and that the pharmacy ships to their state legally.

Summary of Access Pathways: A Decision Tree for Patients

Patients asking "how do I get sermorelin?" in 2026 face a decision with three practical branches:

1. Standard 503A access: A telehealth or in-person provider prescribes sermorelin; a licensed 503A compounder dispenses it. This is the most common route, costing $100, $350 per month cash-pay, reducible with HSA/FSA funds.

2. Clinical trial enrollment: Occasional investigator-initiated trials studying GHRH analogues in specific populations (e.g., older adults with low IGF-1, metabolic syndrome) may provide sermorelin at no cost. Searching ClinicalTrials.gov for "sermorelin" filters active recruiting studies [12].

3. Formal expanded access IND: Applicable only to patients with a serious or immediately life-threatening condition who have exhausted approved alternatives. A treating physician submits FDA Form 3926 directly to the FDA. This pathway is rarely appropriate for sermorelin given that FDA-approved somatropin products exist for diagnosed AGHD [1].

For the vast majority of adult patients, Branch 1 is the applicable route. Patients who qualify for an active clinical trial should consider Branch 2 before paying out-of-pocket.

The Endocrine Society recommends that adult GHD diagnosis be confirmed with a stimulation test (insulin tolerance test or glucagon stimulation test) before initiating any GH-axis therapy, with an IGF-1 below -2 SD for age as a supporting criterion [3]. Meeting that diagnostic standard strengthens both the clinical rationale for treatment and the HSA/FSA documentation basis.